Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 3/20 | 0.31 |
| ▸ | GABRD | O14764 | 3/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322735 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL28906024 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL28038303 | 0.84 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL28038302 | 0.84 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL1517244 | 0.84 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL24425369 | 0.84 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL25409398 | 0.84 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL2785642 | 0.84 | SLC7A5 (0.57) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL7530284 | 0.78 | LMNA (0.38) | SLC7A5TP53ALOX5ALDH1A1MAPT | |
| SCHEMBL13502414 | 0.76 | SLC7A5 (0.60) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001395-A2 | PREVENTION AND TREATMENT OF INFLUENZA WITH GLUTAMINE ANTAGONIST AGENTS | UNIVERSITY OF SOUTH CAROLINA (US) | 2007-01-04 | — | — | WO | claimed |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-02-08 | — | — | US | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3328375-B1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | UNIV JOHNS HOPKINS (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220241299-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2022-08-04 | — | — | US | disclosed |
| CN-108135875-B | Methods and compositions for treating metabolic reprogramming disorders | 约翰霍普金斯大学 | 2021-12-31 | — | — | CN | disclosed |
| CN-108348492-B | Methods for cancer and immunotherapy using glutamine analogs | 约翰霍普金斯大学 | 2021-09-28 | — | — | CN | disclosed |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3328375-A2 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3328374-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3328376-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023791-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023793-A2 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023787-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20160008380-A1 | TARGETING GLUTAMINE METABOLISM IN BRAIN TUMORS | UNIV JOHNS HOPKINS (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2014138391-A1 | TARGETING GLUTAMINE METABOLISM IN BRAIN TUMORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2007001395-A2 | PREVENTION AND TREATMENT OF INFLUENZA WITH GLUTAMINE ANTAGONIST AGENTS | UNIVERSITY OF SOUTH CAROLINA (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060276438-A1 | Prevention and treatment of influenza with glutamine antagonist agents | UNIVERSITY OF SOUTH CAROLINA | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | SLC7A5 109/4885SLC1A3 54/4885SLC1A2 20/4885 |
| US-20220241299-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | SLC7A5 77/4885SLC1A3 21/4885SLC1A2 3/4885 |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | GLUL, GLS2, SLC1A2 | SLC7A5 77/4885SLC1A3 21/4885SLC1A2 3/4885 |
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | SLC7A5 77/4885SLC1A3 21/4885SLC1A2 3/4885 |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | GLS, GLUL, ASNS | SLC7A5 310/4885SLC1A3 18/4885SLC1A2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.